{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=22",
    "query": {
      "condition": "Melanoma Neoplasms",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 2205,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T07:17:55.268Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02519322",
      "title": "Neoadjuvant and Adjuvant Checkpoint Blockade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Melanoma",
        "Mucosal Melanoma",
        "Ocular Melanoma",
        "Stage III Acral Lentiginous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIB Uveal Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IIIC Uveal Melanoma AJCC v7",
        "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2016-02-02",
      "completion_date": "2023-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519322"
    },
    {
      "nct_id": "NCT00162123",
      "title": "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2006-05",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Laverne, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Laverne",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00162123"
    },
    {
      "nct_id": "NCT01508013",
      "title": "An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Appearance-Focused Website Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Website",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "East Tennessee State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 443,
      "start_date": "2011-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-02",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 1,
      "location_summary": "Johnson City, Tennessee",
      "locations": [
        {
          "city": "Johnson City",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01508013"
    },
    {
      "nct_id": "NCT07215988",
      "title": "Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a \"Filter\" Observational Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Locally Advanced Basal Cell Carcinoma",
        "Locally Advanced Malignant Skin Neoplasm",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Mucosal Melanoma",
        "Locally Advanced Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Non-Interventional Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2026-02-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215988"
    },
    {
      "nct_id": "NCT05756556",
      "title": "T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "T3011 + Cobimetinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "ImmVira Pharma Co. Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2024-06-30",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 1,
      "location_summary": "Canton, Ohio",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756556"
    },
    {
      "nct_id": "NCT00470015",
      "title": "Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "MART-1 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp100 antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MART-1a peptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-03",
      "completion_date": "2013-01-02",
      "has_results": false,
      "last_update_posted_date": "2019-02-19",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470015"
    },
    {
      "nct_id": "NCT05577182",
      "title": "Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "INCA32459-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2023-01-05",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05577182"
    },
    {
      "nct_id": "NCT02451488",
      "title": "Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2015-05",
      "completion_date": "2016-11-04",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451488"
    },
    {
      "nct_id": "NCT03385486",
      "title": "Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "TBX-3400",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Taiga Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2019-06-02",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Denver, Colorado",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03385486"
    },
    {
      "nct_id": "NCT03637803",
      "title": "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Oncology",
        "Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Melanoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "MRx0518",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "4D pharma plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2019-01-10",
      "completion_date": "2023-05-08",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-10-15T07:17:55.268Z",
      "location_count": 5,
      "location_summary": "Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03637803"
    }
  ]
}